AVANT Immunotherapeutics, Inc. is a biopharmaceutical company that uses novel applications of immunology to develop products for the prevention and treatment of diseases. The Company is developing a portfolio of vaccines and immunotherapeutics addressing applications, including cardiovascular disease, bacterial and viral diseases, and biodefense and food safety. These include single-dose, oral vaccines that protect against important disease-causing agents, a novel vaccine candidate for cholesterol management and a treatment to reduce complement-mediated tissue damage associated with cardiac by-pass surgery. The Company's wholly owned subsidiaries are AVANT TC Merger Corp. and Virus Research Institute, Inc. (VRI). The Company is building business franchises in three disease areas: cardiovascular diseases, including cholesterol management, bacterial vaccines and viral vaccines.